Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome.

• DOI: 10.3290/j.ohpd.a30172
• Publication Date: 2013-01-01
• Authors: Gonca Mumcu; Müge Bıçakçıgil; Neslihan Yılmaz; Hale Ozay; Ümit Karaçaylı; Hale Cimilli; Şule Yavuz
• Keywords: Hydroxychloroquine; Sjögren syndrome

Purpose Some evidence implicates a role of hydroxychloroquine (HQ) in the management Sjogren's syndrome. This study evaluated effect HQ on saliva B-cell activating factor (BAFF) levels as well health related quality life (QoL) patients with primary syndrome (pSS). Materials and methods Ten pSS who had been treated for at least 2 years 15 healthy controls (HC) were included study. First, was withdrawn 12 weeks, then baseline evaluation performed. Subsequently, restarted further evaluations carried out after 24 weeks treatment. Oral infection foci eliminated by dental periodontal treatments both groups before enrollment. BAFF ELISA serum unstimulated mixed saliva. Salivary flow rates control group measured well. an oral impact profile-14 (OHIP-14) questionnaire. Results (median: 12.39 ng/ml) significantly decreased using (2.78 ng/ml, P = 0.008) (0.54 0.011). Similarly, decreases (5.23 seen treatment (2.18 0.008 0.0 0.012, respectively). Serum salivary lower (0.37 ng/ml resp.) compared to those therapy (P 0.006 0.001, resp.). Unstimulated flows similar (0.38 ml/min) (0.50 0.51) but higher than patients' rate (0.04 0.008). Conclusion lowered when HQ. In addition, disease activity increased can be achieved patients.